PresentationKatja LangeSenior VP & Chief Business Officer Good morning, and thank you so much for joining us today. I'm Kat Lange, Chief Business Officer at Avidity Biosciences. Today, we are excited to share the first functional data from the EXPLORE44 open-label extension study of Del-zota for boys and young men living with DMD44. Before we get started, I would like to share that this presentation contains forward-looking statements as defined under applicable law. Forward-looking statements involve risks ...